Moody Aldrich Partners LLC Sells 137,348 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Moody Aldrich Partners LLC lowered its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 63.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 79,145 shares of the company’s stock after selling 137,348 shares during the quarter. Moody Aldrich Partners LLC’s holdings in NewAmsterdam Pharma were worth $2,034,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of NAMS. Frazier Life Sciences Management L.P. increased its stake in shares of NewAmsterdam Pharma by 5.1% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock worth $213,396,000 after purchasing an additional 628,251 shares during the last quarter. Janus Henderson Group PLC increased its stake in shares of NewAmsterdam Pharma by 51.1% during the 3rd quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company’s stock worth $25,607,000 after purchasing an additional 520,772 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of NewAmsterdam Pharma by 1,231.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock worth $3,972,000 after purchasing an additional 221,305 shares during the last quarter. Millennium Management LLC increased its stake in shares of NewAmsterdam Pharma by 23.0% during the 2nd quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock worth $22,388,000 after purchasing an additional 217,902 shares during the last quarter. Finally, Readystate Asset Management LP purchased a new stake in shares of NewAmsterdam Pharma during the 3rd quarter worth approximately $2,009,000. Institutional investors own 89.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on NAMS shares. Needham & Company LLC restated a “buy” rating and set a $36.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Royal Bank of Canada reiterated an “outperform” rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Scotiabank lifted their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research note on Wednesday, December 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma presently has a consensus rating of “Buy” and a consensus target price of $41.60.

NewAmsterdam Pharma Trading Down 5.1 %

NewAmsterdam Pharma stock opened at $21.45 on Wednesday. NewAmsterdam Pharma has a 1-year low of $15.19 and a 1-year high of $27.29. The firm has a 50 day simple moving average of $23.46 and a 200 day simple moving average of $19.95.

Insider Activity

In other news, major shareholder Nap B.V. Forgrowth sold 29,846 shares of the business’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $25.54, for a total transaction of $762,266.84. Following the completion of the transaction, the insider now directly owns 10,656,172 shares in the company, valued at $272,158,632.88. The trade was a 0.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 446,730 shares of company stock worth $11,438,695 in the last three months. Corporate insiders own 19.50% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.